Study #2025-0475
A phase 2, multicenter, randomized, open-label trial to evaluate safety and efficacy of two dose levels of Quizartinib as maintenance for adult patients with newly diagnosed FLT3-ITD (+) acute myeloid leukemia in complete remission (comparison of two dose levels of Quizartinib as maintenance in FLT3-ITD (+) acute myeloid leukemia patients in complete remission)
MD Anderson Study Status
Enrolling
Treatment Agent
Quizartinib High Dose, Quizartinib Low Dose
Description
This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia, Leukemia
Study phase:
Phase II
Physician name:
Tapan Kadia
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?